Navigation Links
Cambrex Reports Fourth Quarter and Full Year 2009 Results
Date:2/10/2010

er costs related to the development of new products and technologies.

Operating Profit increased to $3.7 million in the fourth quarter 2009 from $1.8 million in the fourth quarter 2008.  Excluding Restructuring Expenses and Strategic Alternative Costs of $3.3 million recorded in 2008, Operating Profit decreased $1.4 million quarter over quarter.  EBITDA was $9.4 million, or 16.0% of sales, compared to Adjusted EBITDA of $10.5 million, or 16.0% of sales last year.

The Provision for Income Taxes totaled $5.7 million in the fourth quarter 2009 compared to $1.1 million in the fourth quarter 2008.  Provision for Income Taxes includes a $5.3 million expense in the fourth quarter 2009 related to an ongoing audit of a European subsidiary.  The Company's effective tax rates have been and are expected to remain highly sensitive to the geographic mix of income due to the Company's inability to recognize tax benefits where there has been a recent history of losses, primarily in the U.S.

Net Loss for the fourth quarter 2009 was $2.8 million or $0.09 per share compared to $1.0 million or $0.03 per share in the fourth quarter 2008.  

Capital expenditures and depreciation for the fourth quarter 2009 were $2.9 million and $5.7 million compared to $7.3 million and $4.9 million in the fourth quarter 2008, respectively.  The decrease in capital expenditures is largely due to fourth quarter 2008 spending o
'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports First Quarter 2009 Results
7. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... Francisco, CA (PRWEB) March 25, 2015 ... Support for Novel Mechanism of Action in Neuromuscular ... 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... fast skeletal muscle troponin activator tirasemtiv in the ... a Phase IIa “Evidence of Effect” or hypothesis-generating ...
(Date:3/25/2015)... and the HAGUE, Netherlands , March ... of LES Stimulation therapy for chronic gastro-esophageal reflux disease ... Surgery [ Surgery . 2015; 157(3):556-567 ], ... minimally-invasive therapy. The study included 25 ... 11 years and taking prescribed daily proton pump inhibitor ...
(Date:3/25/2015)... COLLEGE PARK, Md. , March 25, 2015 ... of two years of intense research by scientists ... University of Maryland and represent a breakthrough in ... an assistant professor in the Department of Animal & ... faculty research assistant in ANSC, successfully produced genome-edited ...
(Date:3/25/2015)... , March 25, 2015  CASI Pharmaceuticals, Inc. ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a commercial focus on China ... 2 trial of its target therapy drug candidate ENMD-2076 ... of Chinese Academy of Medical Sciences in ...
Breaking Biology Technology:Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 3University of Maryland Researchers Successfully Produce Genome-edited Pigs Using Revolutionary Technology 2CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 2CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 3CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 4CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 5
... DALLAS, Aug. 13 Access Pharmaceuticals, Inc.,(OTC Bulletin Board: ... the Fourth Annual Noble Financial Equity Conference to be ... Resort, Nevada. Jeffrey B. Davis,CEO of Access is scheduled ... a.m.,Pacific time (12:00 noon Eastern), and will give a ...
... Additional Testing Services Provided by Interleukin ... ... Aug. 13 ,Interleukin Genetics, Inc. (Amex: ILI ), and OralDNA ... agreement,for Interleukin Genetics, proprietary PST(R) Genetic Test. The PST(R),Genetic Test provides ...
... the benefits of its Bio-Forge® product line through the use of ... an overview of Stoller,s proprietary technology, plant growth cycles and hormone ... them to flourish. , ... Houston, TX (PRWEB) August ...
Cached Biology Technology:Access Pharmaceuticals to Present at the Noble Financial Equity Conference 2Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs 2Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs 3Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs 4StollerUSA Launches Bio-Forge.com to Offer Solutions for Crops Under Stress 2StollerUSA Launches Bio-Forge.com to Offer Solutions for Crops Under Stress 3
(Date:3/12/2015)... 2015 Beta Systems today ... access management (IAM) solution for a fixed price ... System,s new IAM package, customers benefit from the ... multiple IAM implementations across different industries. The new ... as any necessary services and consulting. It spans ...
(Date:3/11/2015)... , Mar. 11, 2015 Research and Markets ... of the "Access Control Market by Product, Application ... 2020" report to their offering. , ... expected to reach $10.4 billion by 2020, with an ... market report covers the products types such as contact ...
(Date:3/10/2015)... 10, 2015  Continuing its 167-year history of offering ... introduces The Eye Scanning Password Authenticator , a ... to secure websites or sensitive data. Employing ... international borders, the device has a small camera that ... the iris, converting them into an encrypted ID that ...
Breaking Biology News(10 mins):Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... led by biologists at the University of California, San ... them susceptible to Bacillus thuringiensis toxin, or Bt toxin--a ... farmers and in genetically engineered crops to ward off ... and use of Bt toxins to prevent insects, which ...
... to inheritance laws the scientific world has accepted ... to normal traits carried by their grandparents, bypassing ... mutant parent plants apparently have hidden templates containing ... be transferred to their offspring, even though the ...
... here have used a new microscopic, three-dimensional scaffolding to coax ... then to function identical to how fat cells naturally do ... fat cells, or adipocytes, in the laboratory, those cells never ... tissue. They failed to produce the genetic and biologic components ...
Cached Biology News:UCSD discovery may help extend life of natural pesticide 2UCSD discovery may help extend life of natural pesticide 3Plants defy Mendel's inheritance laws, may prompt textbook changes 2Plants defy Mendel's inheritance laws, may prompt textbook changes 3Tiny scaffolding allows stem cells to become working fat cells 2Tiny scaffolding allows stem cells to become working fat cells 3
...
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
... are macroporous polystyrene beads for hydrophobic interaction ... for adsorbing organics of molecular weight less ... are useful for the adsorption of nonpolar ... the removal of detergents such as Triton ...
... : Fusion protein corresponding to ... human Mi-2 Formulation: 0.7M Tris-glycine, ... sodium azide, containing 30% glycerol ... immunoblot on Hela nuclear extract ...
Biology Products: